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Abstract 
Ghrelin, the endogenous ligand of the GH secretagogue receptor, has a pleiotropic role in the modulation of 
energy balance. Recent evidence has demonstrated that besides its orexigenic role, ghrelin regulates central 
and peripheral lipid metabolism through specific control of hypothalamic AMP-activated protein kinase 
(AMPK), a critical metabolic gauge regulating both cellular and whole-body energy homeostasis. In this 
review, we summarize the new milestones of ghrelin's actions on energy balance, with particular focus on its 
molecular interaction with hypothalamic AMPK and fatty acid metabolism. Understanding this new 
metabolic pathway can provide new therapeutic targets for the treatment of obesity and the metabolic 
syndrome. 
Ghrelin: a stomach-derived peptide modulating energy balance 
A large degree of attention has surrounded the prospect of ghrelin becoming a key factor in the 
fight against obesity. This 28 amino acid peptide hormone, with orexigenic properties produced in 
the stomach (Kojima et al. 1999, Tschop et al. 2000, Nakazato et al. 2001, Seoane et al. 2003, 
Nogueiras et al. 2004, López et al. 2008a), shows several characteristics that lead researchers to 
believe that its potential as antiobesity target is genuine (Foster-Schubert & Cummings 2006, 
Zorrilla et al. 2006). Investigations involving both humans and rodents have shown that ghrelin 
promotes feeding, weight gain, and adiposity (Tschop et al. 2000, Wren et al. 2001a). In fact, 
there is an inverse relationship between circulating ghrelin levels and body weight (Tschop et al. 
2001b). Opposite, increased levels of ghrelin have been detected in patients diagnosed with 
Prader–Willi syndrome (Cummings et al. 2002). Moreover, research using ghrelin knockout (KO) 
mice (Wortley et al. 2005) or ghrelin receptor KO (GHS-R KO) mice (Zigman et al. 2005) has 
demonstrated that lack of ghrelin or ghrelin signaling protects against diet-induced obesity. 
Altogether, these data demonstrate that ghrelin is an important hormonal signal, promoting feeding 
and modulating circadian control of feeding patterns in humans and rodents (Cummings et al. 
2001, Tschop et al. 2001a, Drazen et al. 2006).  
  
The ‘classical’ mechanism mediating ghrelin orexigenic effect 
The effect of ghrelin on feeding is mediated through the GH secretagogue receptor 1a (GHS-R 
1a), as indicated by the lack of ghrelin's orexigenic effect in GHS-R KO mice (Sun et al. 2004). 
The relevance of this receptor is further supported by anatomical data showing that GHS-R 1a is 
highly expressed in hypothalamic cell populations that regulate feeding and body weight 
homeostasis, such as agouti-related peptide/neuropeptide Y (AGRP/NPY) neurons in the arcuate 
nucleus (ARC) and fatty acid synthase (FAS) neurons in the ventromedial nucleus (VMH; Bennett 
et al. 1997, Guan et al. 1997, Tannenbaum et al. 1998, Willesen et al. 1999, Mitchell et al. 2001, 
Nogueiras et al. 2004, Smith 2005, Zigman et al. 2006, López et al. 2008a, Lage et al. 2010). 
GHS-R 1a expression is not widespread, as it is absent in other regions, such as the lateral 
hypothalamic area (LHA; Guan et al. 1997), where a large number of orexigenic cell populations, 
such as orexins (OXs; Broberger et al. 1998, Elias et al. 1998, de Lecea et al. 1998, Peyron et al. 
1998, Sakurai et al. 1998, Horvath et al. 1999, Seoane et al. 2003) and melanin-concentrating 
hormone (MCH)-producing neurons are located (Nahon et al. 1989, Bittencourt et al. 1992, Qu et 
al. 1996).  
 
Along with this morphological evidence, central treatment with ghrelin massively increases the 
mRNA expression of the orexigenic neuropeptides AGRP and NPY in the ARC (Fig. 1), in fed or 
fasted rodents, an effect that is gender independent (Kamegai et al. 2001, Nakazato et al. 2001, 
Seoane et al. 2003, Lage et al. 2010). Ghrelin has also been reported to inhibit the firing of 
proopiomelanocortin (Pomc) neurons by increasing the frequency of spontaneous synaptic γ-
aminobutyric acid release onto them (Cowley et al. 2003, Andrews et al. 2008), without affecting 
Pomc mRNA expression (Kamegai et al. 2000, 2001). Confirming that ghrelin's orexigenic effect 
is mediated by specific modulation of AGRP/NPY neurons in the ARC, no change was 
demonstrated in the mRNA levels of the other feeding-promoting neuropeptides, such as MCH 
and prepro-OX (Seoane et al. 2003). The physiological relevance of this molecular mechanism 
was firmly established using ghrelin in KO mice. Of interest, AGRP KO or NPY KO responded 
normally to ghrelin; however, the double AGRP/NPY KO failed to respond to ghrelin, indicating 
the existence of redundancy among these two neuropeptides as mediators of ghrelin's orexigenic 
action (Chen et al. 2004).  
 
 
 
Figure 1. The ‘classical’ mechanism under ghrelin orexigenic effect. Ghrelin, 
acting on GH secretagogue receptor 1a (GHS-R 1a), stimulates the expression of 
hypothalamic homeobox domain transcription factor (BSX), forkhead box O1 
(FOXO1), and the phosphorylated cAMP response-element-binding protein 
(pCREB). Subsequently, agouti-related peptide (Agrp) and neuropeptide Y (Npy) 
gene expressions are increased in the arcuate nucleus of the hypothalamus (ARC).   
In addition to the control of the circadian patterns of feeding, the interaction between ghrelin 
and ARC neurons is also important in the metabolic adaptation to fasting, a situation characterized 
by elevated ghrelin-circulating levels (Tschop et al. 2000, Wren et al. 2001a, Nogueiras et al. 
2004, López et al. 2008a). This is demonstrated by the fact that starvation-induced hunger and 
food intake are suppressed after central administration of anti-ghrelin antiserum (Nakazato et al. 
2001). Indeed, it is worth mentioning that even in this state of hyperghrelinemia, the 
administration of this peptide to food-deprived rats led to a further increase in Agrp and Npy 
mRNA contents in the ARC, suggesting that this interaction is fundamental for hunger to occur 
(Seoane et al. 2003). It is also important that the ghrelin-induced fasting effect is also mediated by 
specific modulation of GHS-R. Thus, in the ARC of fasted rats (and also of obese Zucker rats, 
which lack leptin signaling), GHS-R expression is significantly increased in comparison to 
controls, an effect that can be blunted with central leptin replacement (Nogueiras et al. 2004). The 
physiological relevance of leptin action on GHS-R is unclear but it has been proposed that, 
considering that GHS-R is reported to be constitutively active (Holst et al. 2003), leptin 
downregulates GHS-R expression in the ARC in an attempt to decrease orexigenic signaling 
(Nogueiras et al. 2004). Consistently, ghrelin significantly increased GHS-R expression in the 
ARC of normal rats (Bennett et al. 1997, Nogueiras et al. 2004), demonstrating that both leptin 
and ghrelin have a dual and opposite role in modulating the GHS-R expression in the ARC.  
BSX, forkhead box O1, and CREB are the key transcription factors in ghrelin receptor 
signaling pathway 
Although the role of ghrelin as the main modulator of ARC-derived neuropeptides is well 
established, the molecular mechanisms mediating this action have just been identified. It has been 
recently reported that the hypothalamic homeobox domain transcription factor BSX is highly 
expressed in AGRP/NPY neurons in the ARC and regulates ghrelin's stimulatory effect on Agrp 
and Npy gene expression in male and female rodents (Sakkou et al. 2007, Nogueiras et al. 2008a, 
Lage et al. 2010). Although both genes share BSX as a common transcriptional factor, BSX needs 
to interact with another two transcription factors to activate Agrp and Npy mRNA expression: the 
forkhead box O1 (FOXO1) for Agrp gene and the phosphorylated cAMP response-element-
binding protein (pCREB) for Npy gene respectively (Shimizu-Albergine et al. 2001, Kitamura et 
al. 2006, Nogueiras et al. 2008a, Lage et al. 2010). Our group has shown that BSX, FOXO1, and 
pCREB protein expression in the hypothalamus are stimulated after central ghrelin administration, 
also in a gender-independent manner (Fig. 1; Lage et al. 2010). Interestingly, the ghrelin–BSX–
FOXO1–pCREP–AGRP/NPY pathway seems to exhibit a nucleus-specific pattern, since BSX 
expression in the dorsomedial nucleus of the hypothalamus (DMH) is unaffected by central ghrelin 
treatment (Nogueiras et al. 2008a).  
 
The ghrelin-induced increase in FOXO1 protein levels is particularly interesting, since it 
affects both the nonphosphorylated (FOXO1) and the phosphorylated (pFOXO1) forms (Lage et 
al. 2010). Recent evidence has shown that hormonal signals, such as leptin and insulin, regulate 
Agrp and Pomc gene expression through modulation of the balance between FOXO1 (active form) 
and pFOXO1 (inactive form). Thus, leptin and insulin promote pFOXO1 and prevent its 
translocation to the nucleus (Kim et al. 2006). This results in increased expression of Pomc 
(Belgardt et al. 2008, Ernst et al. 2009, Plum et al. 2009) and decreased expression of Agrp 
(Kitamura et al. 2006). Quite opposite to leptin and insulin, we demonstrated that central ghrelin 
administration increased both hypothalamic FOXO1 and pFOXO1 to a similar extent. Consistent 
with previous literature, elevated levels of FOXO1 would be the mechanism leading to an 
increased transcription rate of the Agrp gene by ghrelin (Kitamura et al. 2006); however, the 
physiological relevance of increased pFOXO1 is unclear. Recent evidence has revealed that in 
pancreatic β-cells, ghrelin also stimulates both FOXO1 and pFOXO1 (Wang et al. 2010a). In this 
context, increased levels of pFOXO1 after ghrelin treatment elicit a protective effect against 
lipotoxicity, as shown by inhibition of endoplasmic reticulum (ER) stress and reduced levels of 
C/EBP homologous protein (CHOP-10; Wang et al. 2010a), a pro-apoptotic member of the C/EBP 
family of transcription factors (Ron & Habener 1992, Oyadomari & Mori 2004), which is known 
to inhibit cell differentiation in response to metabolic stress (Tang & Lane 2000, Martínez de 
Morentin et al. 2010b, de Morentin & López 2010, Wang et al. 2010b). Similarly, ghrelin seems to 
protect against lipotoxicity-induced apoptosis and ER stress in an ischemic heart model (Zhang et 
al. 2009). Consistent with these observations, we demonstrated that ghrelin reduces the 
hypothalamic levels of CHOP-10 and the phosphorylated form of its upstream regulator 
phosphorylated eukaryotic translation initiation factor 2α (peIF2α; Lage et al. 2010). Taking into 
account that 1) hypothalamic ER stress has recently been suggested as a pathophysiological 
mechanism mediating leptin resistance and obesity (Hosoi et al. 2008, Zhang et al. 2008, Ozcan et 
al. 2009, Martínez de Morentin et al. 2010b, de Morentin & López 2010, Ropelle et al. 2010) and 
2) central ghrelin administration increases hypothalamic reactive oxygen species (ROS; Andrews 
et al. 2008), which are well-recognized ER-stress inducers (Lee et al. 2007, Tagawa et al. 2008, 
Medina-Gomez et al. 2009, Santos et al. 2009, Martínez de Morentin et al. 2010b), we have 
recently proposed that ghrelin-induced elevation in hypothalamic pFOXO1 might be part of an 
allostatic response protecting against ER stress (Lage et al. 2010), a hypothesis that will involve 
further investigation.  
Hypothalamic fatty acid metabolism: a housekeeping pathway modulating whole-body 
energy balance 
Fatty acids are derived either from the diet or by de novo synthesis. The basic pathway for de 
novo fatty acid synthesis is summarized in Fig. 2 (Ruderman et al. 2003, Dowell et al. 2005, 
López et al. 2007, Lage et al. 2008, Martínez de Morentin et al. 2010a). Under lipogenic 
conditions, excess glucose in the cell is first converted to pyruvate via glycolysis in the cytoplasm. 
Pyruvate enters the mitochondria and is converted to acetyl-CoA and transported as citrate from 
the mitochondria into the cytoplasm. ATP citrate lyase then reconverts citrate to acetyl-CoA. 
Acetyl-CoA carboxylase (ACC) catalyzes the carboxylation of acetyl-CoA to malonyl-CoA in an 
ATP-dependent manner. Acetyl-CoA and malonyl-CoA are then used as the substrates for the 
production of palmitate by the seven enzymatic reactions catalyzed by FAS, at the expense of 
NADPH. The synthesis step of malonyl-CoA can be reversibly regulated as malonyl-CoA 
decarboxylase (MCD) converts malonyl-CoA back to acetyl-CoA. The resulting saturated fatty 
acid molecule produced by FAS can be subsequently desaturated to form unsaturated fatty acids, 
to contribute to the triglyceride pool, or be directed to specific biosynthetic pathways for the 
synthesis of phospholipids and derivatives for membrane and signaling functions (Kahn et al. 
2005, López et al. 2007). Alternatively, fatty acids can also be further metabolized depending on 
requirements. During fatty acid oxidation, fatty acids are first activated in the outer mitochondrial 
membrane in a reaction catalyzed by long-chain fatty acyl-CoA synthetase. Next, they are 
translocated to the mitochondrial matrix, by the action of carnitine palmitoyltransferase 1 and 2 
(CPT1 and CPT2), where oxidation takes place (Kahn et al. 2005, López et al. 2007). The 
complete oxidation of a palmitate molecule (C16:0) yields 129 molecules of ATP.  
  
 
 
 
Figure 2. Fatty acid synthesis pathway. Excess glucose in the cell is first 
converted to pyruvate via glycolysis in the cytoplasm. Pyruvate enters the 
mitochondria and is converted to acetyl-CoA and transported as citrate from 
the mitochondria to the cytoplasm. ATP citrate lyase (ACL) then reconverts 
citrate to acetyl-CoA. Acetyl-CoA carboxylase (ACC) catalyzes the 
carboxylation of acetyl-CoA to malonyl-CoA. Both acetyl-CoA and malonyl-
CoA are then used as the substrates for the production of palmitate catalyzed 
by fatty acid synthase (FAS). Malonyl-CoA decarboxylase (MCD) converts 
malonyl-CoA back to acetyl-CoA. Fatty acids are esterified in a reaction 
catalyzed by long-chain fatty acyl-CoA synthetase (LCFACS). Carnitine 
palmitoyltransferase 1 (CPT1) is the enzyme importing long-chain fatty acyl-
CoA, such as palmitoyl-CoA, into the mitochondria for fatty acid oxidation; 
CPT1 activity is allosterically inhibited by malonyl-CoA. The resulting 
saturated fatty acid molecule produced by FAS can be further metabolized 
depending on the requirements, desaturated to form unsaturated fatty acids, 
derived to triglyceride molecules, or channeled to a range of phospholipids and 
derivatives for membrane and signaling functions. AMP-activated protein 
kinase (AMPK) is a serine/threonine protein kinase composed of a catalytic 
subunit (α1 or α2) and two regulatory subunits (β1 or β2 and γ1 or γ2 or γ3), 
which controls ACC, MCD, and FAS activities. Upstream regulation of AMPK 
is mediated by a complex mechanism involving several proteins such as LKB1 
Ca2+/calmodulin-dependent protein kinase kinase 1 or 2 (CAMKK1 or 
CAMKK2), transforming growth factor-β-activated kinase (TAK1), kinase 
suppressor of Ras (KSR2), protein phosphatase 2C α (PP2Cα), and cell-death-
inducing-like-effector A (CIDEA), as well as cellular AMP concentration.  
 
  
The activities of ACC and MCD are regulated by phosphorylation by AMP-activated protein 
kinase (AMPK). AMPK is a serine/threonine protein kinase composed of a catalytic subunit (α1 or 
α2) and two regulatory subunits (β1 or β2 and γ1 or γ2 or γ3). AMPK is activated by 
phosphorylation on Thr172 of the α subunit, a process catalyzed by LKB1 or Ca2+/calmodulin-
dependent protein kinase kinase 1 or 2 (CAMKK1 or CAMKK2; Ruderman et al. 2003, Hawley et 
al. 2005, Kahn et al. 2005, Woods et al. 2005, Carling et al. 2008, Lage et al. 2008, Martínez de 
Morentin et al. 2010a). Transforming growth factor-β-activated kinase (TAK1; Xie et al. 2006) 
also activates AMPK, and kinase suppressor of Ras (KSR2) interacts with the α1 subunit of 
AMPK, modulating its activity (Costanzo-Garvey et al. 2009). The current data also point out that 
protein phosphatase 2Cα (PP2Cα) inactivates AMPK by dephosphorylation (Steinberg et al. 
2006a, Martínez de Morentin et al. 2010a). AMPK is also allosterically activated by AMP, which 
also inhibits PP2C, increasing phosphorylation in Thr172. Finally, recent data have revealed that 
cell-death-inducing like-effector A (CIDEA) forms a complex with the β subunit of AMPK, which 
elicits an ubiquitination-mediated degradation of AMPK, reducing its activity (Fig. 2; Qi et al. 
2008). Whatever the mechanism, activated (phosphorylated) AMPK is a counter-regulatory 
response to avoid ATP depletion in many tissues, leading to a switching off of ATP-consuming 
processes (such as fatty acid synthesis), while switching on catabolic processes that produce ATP 
(such as fatty acid β-oxidation) and restore the AMP:ATP ratio (Ruderman et al. 2003, Kahn et al. 
2005, Carling et al. 2008, Lage et al. 2008, Martínez de Morentin et al. 2010a). In the particular 
case of the lipid metabolism, activated (phosphorylated) AMPK phosphorylates and inhibits ACC 
(pACC), while activating MCD (Ruderman et al. 2003, Dowell et al. 2005, López et al. 2007, 
Lage et al. 2008, Martínez de Morentin et al. 2010a). In addition, activated AMPK decreases FAS 
mRNA expression via a sterol regulatory element-binding protein-1 (SREBP-1)-dependent 
mechanism (Zhou et al. 2001, López et al. 2008a,b). Thus, the overall effect of AMPK activation 
reduces malonyl-CoA and the flux of substrates in the fatty acid biosynthetic pathway.  
 
Evidence gleaned in the last decade has demonstrated that due to the fact that neurons and glial 
cells need lipid synthesis to sustain their metabolic homeostasis, enzymes of fatty acid metabolism 
are constitutively expressed in the brain (López et al. 2007). Importantly, AMPK, ACC, CPT1, 
FAS, and MCD mRNAs and proteins are highly expressed in several metabolically relevant 
hypothalamic nuclei, such as ARC, DMH, paraventricular (PVH), and VMH (Kim et al. 2002, 
Sorensen et al. 2002, Minokoshi et al. 2004, López et al. 2006, 2008a,b, 2010, Chakravarthy et al. 
2007, Dai et al. 2007). In addition to this morphological evidence, pharmacologic and genetic 
results have demonstrated that altered levels and activities of these enzymes affect feeding through 
specific modulation of ARC-derived neuropeptides, namely the orexigenic AGRP and NPY, as 
well as the anorexigenic POMC and cocaine and amphetamine-regulated transcript (Loftus et al. 
2000, Obici et al. 2003, Minokoshi et al. 2004, López et al. 2006, 2008a, Wolfgang et al. 2006, 
Chakravarthy et al. 2007). Since these impaired fatty acid metabolism altered the hypothalamic 
pool of either malonyl-CoA (Hu et al. 2003, López et al. 2006, 2008a, 2010, Chakravarthy et al. 
2007, Lage et al. 2010) and/or long-chain fatty acids-CoA (LCFA-CoA; Obici et al. 2003, He et 
al. 2006, Pocai et al. 2006, López et al. 2010), these metabolites have been proposed as signals of 
nutrient abundance able to modulate feeding. Whether alternative hypothalamic lipid metabolites 
are involved in feeding control will require further investigation.  
Hypothalamic AMPK: a crucial mediator of whole-body energy balance 
Similarly to fatty acid metabolism enzymes, AMPK is expressed in several key hypothalamic 
nuclei, including ARC, LHA, PVH, and VMH (Minokoshi et al. 2004, López et al. 2008a, 2010). 
During physiological regulation of feeding, changes of hypothalamic AMPK are critical parts of 
the adaptive response. Fasting stimulates hypothalamic AMPK, while refeeding inhibits it 
(Minokoshi et al. 2004, Lage et al. 2008, López et al. 2008a, Vázquez et al. 2008, Martínez de 
Morentin et al. 2010a). Activation of AMPK in the hypothalamus (by using adenoviruses 
expressing constitutively active AMPK, AMPK-CA) elicits feeding and body weight gain 
(Minokoshi et al. 2004). On the other hand, inhibition of hypothalamic AMPK (by using 
adenoviruses expressing dominant negative AMPK, AMPK-DN) promotes anorexia and weight 
loss (Minokoshi et al. 2004, López et al. 2008a, 2010). Importantly, as with the variations in the 
hypothalamic concentration of malonyl-CoA and LCFA-CoA, alterations in hypothalamic AMPK 
activity are associated with modifications of neuropeptide mRNA levels. Inhibition of 
hypothalamic AMPK with an AMPK-DN isoform decreases the mRNA expression of AGRP and 
NPY in the ARC; on the contrary, overexpression of an AMPK-CA isoform elevates the fasting-
induced expression of AGRP and NPY in the ARC and also MCH in the LHA (Minokoshi et al. 
2004).  
 
Besides the response to starvation, recent evidence has shed light on the central physiological 
role of hypothalamic AMPK in the regulation of energy homeostasis by integrating peripheral 
signals with hypothalamic networks. Of note, the effects of fasting and refeeding on hypothalamic 
AMPK are associated with the changes in circulating nutrients, hormones, and hypothalamic 
neuropeptides (Table 1 and Fig. 3). AMPK activation in several hypothalamic nuclei such as 
VMH, ARC, and PVH has a significant part in mediating counter-regulatory responses to acute 
hypoglycemia, such as attenuated hypoglycemia-induced increases in plasma corticosterone, 
glucagons, and epinephrine (Han et al. 2005, McCrimmon et al. 2006, Alquier et al. 2007, Cotero 
& Routh 2009, Fan et al. 2009), in hypoglycemia sensing (McCrimmon et al. 2004, Murphy et al. 
2009), and glucose production (Yang et al. 2010). In concurrence with these findings, central 
administration of glucose suppresses AMPK activity in the hypothalamus, decreasing feeding 
(Minokoshi et al. 2004, Wolfgang et al. 2007, Cha et al. 2008, Lane & Cha 2009). Metabolites 
also modulate hypothalamic AMPK function. α-Lipoic acid, a cofactor of mitochondrial enzymes 
with antioxidant and anorectic properties (Kim et al. 2004, Ropelle et al. 2008a), citrate (Cesquini 
et al. 2008, Stoppa et al. 2008), and lactate (Cha & Lane 2009) elicit anorexigenic responses 
associated with inhibition of AMPK, activation of ACC, and subsequent increase in malonyl-CoA. 
Furthermore, anorectic hormones, such as leptin, insulin, glucagon-like peptide-1 (GLP-1), ciliary 
neurotrophic factor (CNTF), and melanocortin receptors agonists, including melanotan II (MTII), 
inhibit hypothalamic AMPK (Andersson et al. 2004, Minokoshi et al. 2004, Steinberg et al. 
2006b, Gao et al. 2007, Wolfgang et al. 2007, Seo et al. 2008). In contrast, activation of 
hypothalamic AMPK is caused by orexigenic signals such as AGRP, adiponectin, cannabinoids, 
glucocorticoids, and ghrelin (see later; Andersson et al. 2004, Kola et al. 2005, Kubota et al. 2007, 
Andrews et al. 2008, López et al. 2008a, Shimizu et al. 2008, Lage et al. 2010, Sangiao-Alvarellos 
et al. 2010, Wen et al. 2010). Resistin (RSTN), despite its anorectic effect, activates hypothalamic 
AMPK (Vázquez et al. 2008). Finally, current evidence has demonstrated the hypothalamic 
AMPK mediates thyroid hormone actions on energy balance by controlling the brown adipose 
tissue (BAT) thermogenic program through activation of the sympathetic nervous system (SNS; 
López et al. 2010). Thus, in general, it can be stated that hypothalamic AMPK is a genuine 
element of the energy homeostasis system, as shown in the findings. Interestingly, in spite of the 
vast evidence linking this kinase to peripheral signals (Table 1), the molecular effects of these 
interactions have been mainly investigated only for ghrelin, which are summarized below.  
Table 1. Regulation of hypothalamic AMP-activated protein kinase (AMPK), function of arcuate nucleus (ARC)-derived neuropeptides and feeding 
 
Hypothalamic AMPK 
function 
Agrp mRNA levels in the 
ARC 
Npy mRNA levels in 
the ARC 
Cart mRNA levels 
in the ARC 
Pomc mRNA levels in the 
ARC 
Food intake 
Anorexigenic 
signals       
 α-Lipoic acid 
↓ (Kim et al. 2004, Ropelle et 
al. 2008a)  
– – – – ↓ (Kim et al. 2004, Ropelle et al. 2008a)  
 Citrate 
↓ (Cesquini et al. 2008, Stoppa 
et al. 2008)  
– ↓ (Stoppa et al. 2008)  – ↑ (Stoppa et al. 2008)  
↓ (Cesquini et al. 2008, Stoppa et al. 
2008)  
 CNTF ↓ (Steinberg et al. 2006b)  ↔ (Ziotopoulou et al. 2000)  ↓ (Xu et al. 1998)  
↑ (Ambati et al. 
2007)  
↑ (Ambati et al. 2007)  
↓ (Xu et al. 1998, Ziotopoulou et al. 2000, 
Steinberg et al. 2006b, Ambati et al. 
2007)  
 Feeding 
↓ (Minokoshi et al. 2004, 
López et al. 2008a)  
↓ (Swart et al. 2002, 
Minokoshi et al. 2004, López 
et al. 2008a)  
↓ (Sanacora et al. 
1990, Kalra et al. 1991, 
Swart et al. 2002, 
Minokoshi et al. 2004, 
López et al. 2008a)  
↑ (Kristensen et al. 
1998, Minokoshi et 
al. 2004, López et 
al. 2008a)  
↑ (Schwartz et al. 1997, 
Swart et al. 2002, 
Minokoshi et al. 2004, 
López et al. 2008a)  
↓ (Sanacora et al. 1990, Kalra et al. 1991, 
Kristensen et al. 1998, Swart et al. 2002, 
Minokoshi et al. 2004, López et al. 2006, 
2008a)  
 GLP-1 ↓ (Seo et al. 2008)  ↓ (Seo et al. 2008)  ↓ (Seo et al. 2008)  ↑ (Seo et al. 2008)  ↑ (Seo et al. 2008)  ↓ (Scrocchi et al. 1996, Seo et al. 2008)  
 Glucose 
↓ (McCrimmon et al. 2004, 
2006, Minokoshi et al. 2004, 
Chang et al. 2005, Han et al. 
2005, Wolfgang et al. 2007, 
Cha et al. 2008, Lane & Cha 
2009)  
↓ (Chang et al. 2005, Lee et al. 
2005, Cha et al. 2008)  
↓ (Chang et al. 2005, 
Cha et al. 2008)  
↑ (Cha et al. 2008)  ↑ (Cha et al. 2008)  
↓ (Minokoshi et al. 2004, McCrimmon et 
al. 2004, 2006, Han et al. 2005, Wolfgang 
et al. 2007, Cha et al. 2008, Lane & Cha 
2009)  
 High-protein 
diet/aminoacids 
↓ (Ropelle et al. 2008b)  ↓ (Morrison et al. 2007)  
↓ (Ropelle et al. 
2008b)  
– ↑ (Ropelle et al. 2008b)  ↓ (Ropelle et al. 2008b)  
 Insulin 
↓ (Minokoshi et al. 2004, 
Namkoong et al. 2005)  
↓ (Dunbar et al. 2005, Konner 
et al. 2007) ↔ (Fekete et al. 
2006)  
↓ (Schwartz et al. 
1991, 1992, Sipols et 
al. 1995, Fekete et al. 
2006)  
↔ (Fekete et al. 
2006)  
↑ (Kim et al. 1999, Benoit 
et al. 2002, Fekete et al. 
2006)  
↓ (Woods et al. 1979, Ikeda et al. 1986, 
Schwartz et al. 1992, Minokoshi et al. 
2004, Namkoong et al. 2005)  
 Lactate ↓ (Cha & Lane 2009)  ↓ (Cha & Lane 2009)  ↓ (Cha & Lane 2009)  
↑ (Cha & Lane 
2009)  
↑ (Cha & Lane 2009)  ↓ (Cha & Lane 2009)  
Table 1. Regulation of hypothalamic AMP-activated protein kinase (AMPK), function of arcuate nucleus (ARC)-derived neuropeptides and feeding 
 
Hypothalamic AMPK 
function 
Agrp mRNA levels in the 
ARC 
Npy mRNA levels in 
the ARC 
Cart mRNA levels 
in the ARC 
Pomc mRNA levels in the 
ARC 
Food intake 
 Leptin 
↓ (Minokoshi et al. 2004, Gao 
et al. 2007)  
↓ (Ahima & Flier 2000, Swart 
et al. 2002, Fekete et al. 2006)  
↓ (Ahima & Flier 2000, 
Swart et al. 2002, 
Fekete et al. 2006)  
↑ (Kristensen et al. 
1998, Fekete et al. 
2006)  
↑ (Schwartz et al. 1997, 
Elias et al. 1999, Swart et 
al. 2002, Fekete et al. 
2006)  
↓ (Halaas et al. 1995, Stephens et al. 
1995, Ahima et al. 1996, Schwartz et al. 
1997, Hahn et al. 1998, Kristensen et al. 
1998, Elias et al. 1999, Ahima 2000, 
Swart et al. 2002, Minokoshi et al. 2004, 
Gao et al. 2007, López et al. 2008a)  
 MTII ↓ (Minokoshi et al. 2004)  
↓ (Marsh et al. 1999, Hagan et 
al. 2000, Haskell-Luevano & 
Monck 2001, Haskell-Luevano 
et al. 2001, Trivedi et al. 2003)  
↓ (Fan et al. 1997, 
Murphy et al. 1998, 
Raposinho et al. 2003)  
– 
↑ (Marsh et al. 1999, 
Hagan et al. 2000, 
Haskell-Luevano & 
Monck 2001, Haskell-
Luevano et al. 2001, 
Trivedi et al. 2003)  
↓ (Fan et al. 1997, Murphy et al. 1998, 
Marsh et al. 1999, Hagan et al. 2000, 
Haskell-Luevano & Monck 2001, 
Raposinho et al. 2003, Trivedi et al. 2003, 
Minokoshi et al. 2004, Nogueiras et al. 
2007)  
 RSTN ↑ (Vázquez et al. 2008)  ↓ (Vázquez et al. 2008)  ↓ (Vázquez et al. 2008)  
↑ (Vázquez et al. 
2008)  
↔ (Vázquez et al. 2008)  ↓ (Tovar et al. 2005, Vázquez et al. 2008)  
Orexigenic 
signals       
 Adiponectin 
↑ (Kubota et al. 2007, Guillod-
Maximin et al. 2009, Wen et 
al. 2010)  
– ↑ (Kubota et al. 2007)  – ↓ (Kubota et al. 2007)  ↑ (Kubota et al. 2007)  
 AGRP ↑ (Minokoshi et al. 2004)  ↓ (Korner et al. 2003)  ↔ (Zheng et al. 2002)  
↑ (Zheng et al. 
2002, Korner et al. 
2003)  
↓ (Ollmann et al. 1997, 
Wilson et al. 1999, Marsh 
et al. 1999, Hagan et al. 
2000, Haskell-Luevano & 
Monck 2001, Haskell-
Luevano et al. 2001)  
↑ (Ollmann et al. 1997, Marsh et al. 1999, 
Wilson et al. 1999, Hagan et al. 2000, 
Haskell-Luevano & Monck 2001, 
Haskell-Luevano et al. 2001, Zheng et al. 
2002, Korner et al. 2003, Minokoshi et al. 
2004, López et al. 2008a)  
 Cannabinoids ↑ (Kola et al. 2005, 2008)  ↑ (Gamber et al. 2005)  ↑ (Gamber et al. 2005)  
↓ (Cota et al. 2003, 
Osei-Hyiaman et al. 
2005)  
↓ (Verty et al. 2004, 
Hentges et al. 2005, 
Nguyen & Wagner 2006)  
↑ (Cota et al. 2003, Gamber et al. 2005, 
Kola et al. 2005, 2008, Osei-Hyiaman et 
al. 2005, Nogueiras et al. 2008b)  
 Fasting 
↑ (Minokoshi et al. 2004, 
López et al. 2008a)  
↑ (Swart et al. 2002, 
Minokoshi et al. 2004, López 
et al. 2008a)  
↑ (Sanacora et al. 
1990, Kalra et al. 1991, 
Swart et al. 2002, 
Minokoshi et al. 2004, 
López et al. 2008a)  
↓ (Kristensen et al. 
1998, Li et al. 2002, 
Minokoshi et al. 
2004, López et al. 
2008a)  
↓ (Schwartz et al. 1997, 
Swart et al. 2002, 
Minokoshi et al. 2004, 
López et al. 2008a)  
↑ (Sanacora et al. 1990, Kalra et al. 1991, 
Schwartz et al. 1997, Kristensen et al. 
1998, Swart et al. 2002, Minokoshi et al. 
2004, López et al. 2006, 2008a)  
Table 1. Regulation of hypothalamic AMP-activated protein kinase (AMPK), function of arcuate nucleus (ARC)-derived neuropeptides and feeding 
 
Hypothalamic AMPK 
function 
Agrp mRNA levels in the 
ARC 
Npy mRNA levels in 
the ARC 
Cart mRNA levels 
in the ARC 
Pomc mRNA levels in the 
ARC 
Food intake 
 Ghrelin 
↑ (Andersson et al. 2004, Kola 
et al. 2005, 2008, Andrews et 
al. 2008, López et al. 2008a, 
Lage et al. 2010, Sangiao-
Alvarellos et al. 2010)  
↑ (Kamegai et al. 2000, 2001, 
Nakazato et al. 2001, Seoane 
et al. 2003, Andrews et al. 
2008, López et al. 2008a, Lage 
et al. 2010, Sangiao-Alvarellos 
et al. 2010)  
↑ (Nakazato et al. 
2001, Andrews et al. 
2008, López et al. 
2008a, Lage et al. 
2010, Sangiao-
Alvarellos et al. 2010)  
↔ (Wren et al. 
2000, Hu et al. 
2005)  
↓ (Hu et al. 2005)  
↑ (Tschop et al. 2000, Nakazato et al. 
2001, Wren et al. 2001b, Seoane et al. 
2003, Andersson et al. 2004, Hu et al. 
2005, Kola et al. 2005, 2008, Andrews et 
al. 2008, López et al. 2008a, Lage et al. 
2010, Sangiao-Alvarellos et al. 2010)  
 Glucocorticoids ↑ (Shimizu et al. 2008)  
↑ (Savontaus et al. 2002, Coll 
et al. 2005, Shimizu et al. 
2008)  
↑ (Shimizu et al. 2008)  
↑ (Savontaus et al. 
2002, Vrang et al. 
2003, Germano et 
al. 2007)  
↓ (Arvaniti et al. 2001)  
↑ (Arvaniti et al. 2001, Savontaus et al. 
2002, Vrang et al. 2003, Coll et al. 2005, 
Germano et al. 2007, Shimizu et al. 2008)  
 Glucose 
deprivation 
↑ (McCrimmon et al. 2004, 
2006, Han et al. 2005, Alquier 
et al. 2007, Wolfgang et al. 
2007, Cotero & Routh 2009, 
Fan et al. 2009)  
↑ (Hidaka et al. 2001, Lee et 
al. 2005)  
↑ (Hidaka et al. 2001, 
Sindelar et al. 2002, 
2004, Tkacs & Levin 
2004, Briski & Parihar 
2008, Watanabe et al. 
2008)  
↓ (Nedungadi & 
Briski 2007)  
↓ (Tkacs et al. 2000, 
Nedungadi & Briski 2007)  
↑ (Dryden et al. 1998, Hidaka et al. 2001, 
Sindelar et al. 2002, 2004, McCrimmon et 
al. 2004, 2006, Han et al. 2005, Wolfgang 
et al. 2007)  
       
 
 
 
 
Figure 3. Central ghrelin actions on hypothalamic lipid metabolism and AMPK. Ghrelin, acting on 
GH secretagogue receptor 1a (GHS-R 1a), regulates hypothalamic AMP-activated protein kinase 
(AMPK), phosphorylating (pAMPK) and activating it, which in turn phosphorylates and 
inactivates acetyl-CoA carboxylase (ACC), decreasing the cytoplasmatic pool of malonyl-CoA. 
The net result of this action is an increase in carnitine palmitoyltransferase 1 (CPT1) activity and 
then fatty acid oxidation, which promotes the generation of reactive oxygen species (ROS), which 
are buffered by uncoupling protein 2 (UCP2). This mechanism is critical for ghrelin-induced 
electric activation of agouti-related peptide/neuropeptide Y (AGRP/NPY) neurons, ghrelin-induced 
upregulation of Agrp and Npy gene expression in the ARC, and ghrelin-induced feeding. The 
molecular events connecting the CPT1–ROS–UCP2 axis with the transcription factors (BSX, 
pCREB and FOXO1) involved in the gene expression of Agrp and Npy remain unclear. 
Alternatively, a direct interaction of AMPK, malonyl-CoA, palmitoyl-CoA (or other lipid species) 
with that signaling pathway may be possible. Dotted lines represent indirect or unknown 
interactions.  
Central ghrelin actions on hypothalamic lipid metabolism and AMPK 
Although the ‘classical’ pathway involving AGRP/NPY neurons, and more recently 
BSX–FOXO1–pCREB, has revealed some of the mechanisms underlying the orexigenic 
effect of ghrelin, it was apparent that some of the key factors implicated in the 
transduction pathway of the activated GHS-R1a were still missing. Recent data indicate 
that ghrelin modulates hypothalamic AMPK (Andersson et al. 2004, Kola et al. 2005, 
2008, Andrews et al. 2008, López et al. 2008a,b, Lage et al. 2010, Sangiao-Alvarellos 
et al. 2010). By using a combination of pharmacological, physiological, and genetic 
approaches, several groups, including ours, have demonstrated that the physiological 
orexigenic response to ghrelin involves specific AMPK-induced inhibition of fatty acid 
biosynthesis, which results in decreased hypothalamic levels of malonyl-CoA and 
increased CPT1 activity (Andrews et al. 2008, López et al. 2008a,b, Lage et al. 2010, 
Sangiao-Alvarellos et al. 2010). In this context, ghrelin-induced activation of 
hypothalamic fatty acid oxidation leads to robust changes in hypothalamic 
mitochondrial respiration and production of ROS, which are buffered by uncoupling 
protein 2 (UCP2; Andrews et al. 2008). This mechanism is critical for ghrelin-induced 
electric activation of AGRP/NPY neurons, ghrelin-triggered synaptic plasticity of 
POMC neurons and ghrelin-dependent gene transcription events in those cells (Fig. 3). 
Thus, ghrelin-induced upregulation of Agrp, Npy, Ucp2, Cpt1, and nuclear respiratory 
factor 1 (Nrf1) gene expression is blunted in UCP2 KO mice (Andrews et al. 2008). 
Finally, recent elegant data from Korbonits and colleagues have also demonstrated that 
hypothalamic cannabinoids cross talk with the ghrelin–AMPK signaling. Food intake is 
induced through the cannabinoid receptor type 1 (CB1; Pagotto et al. 2006) and 
stimulation of AMPK (Kola et al. 2005) by both exogenous and endogenous 
cannabinoids. The occurrence of an intact functional CB1 receptor is needed for 
ghrelin's effect on AMPK activity and food intake, as shown in CB1 KO animals, as 
well as using a CB1 antagonist (Kola et al. 2008). These data imply that an intact 
endocannabinoid–CB1 pathway is essential for the AMPK-mediated ghrelin's 
orexigenic effect (Kola et al. 2008).  
 
Although these results provide an interesting mechanism, linking ghrelin-induced 
changes in fatty acid metabolism and neuropeptide expression, one particular caveat 
remained unresolved: how alterations in mitochondrial function could lead to nuclear 
transcriptional events. Our group has recently demonstrated that BSX, FOXO1, and 
pCREB connect ghrelin-promoted activation of hypothalamic fatty acid β-oxidation in 
the mitochondria with nuclear Agrp and Npy gene expression in the ARC (Lage et al. 
2010). Furthermore, we demonstrate that this association is a physiological gender-
independent mechanism modulating feeding. In fact, pharmacological blockage of 
hypothalamic fatty acid β-oxidation, by using the specific CPT1 inhibitor etomoxir, 
blocks the ghrelin-induced effect on BSX and subsequently on Agrp and Npy mRNA 
expression in the ARC of both male and female rats (Lage et al. 2010). Overall, these 
results indicate that the BSX–FOXO1–pCREB signaling pathway plays a key role in 
integrating hypothalamic ghrelin actions. Further experiments, using BSX KO mice 
(Sakkou et al. 2007), are essential to confirm the existence of alternative pathways to 
BSX linking ghrelin fatty acid metabolism and neuropeptide expression. Actually, 
taking into account that BSX KO mice exhibit lower fasting-induced response in Agrp 
and Npy mRNA levels (Sakkou et al. 2007), the involvement of alternative additional 
transcription factors cannot be excluded.  
 
In addition to its effects on the AMPK–malonyl-CoA–CPT1 axis, ghrelin decreases 
FAS expression in a region-specific manner and this effect is AMPK dependent (Fig. 3; 
López et al. 2008a,b). This particular effect is interesting because of its physiological 
significance. The transient response to ghrelin is displayed in the fact that malonyl-CoA 
returns to normal levels only 6 h after the initial decrease (López et al. 2008a). 
Although the process decreasing malonyl-CoA levels may be attributed to the 
termination of ghrelin stimulation of AMPK (and the subsequent ghrelin-induced 
inactivation of ACC by AMPK), recent data also suggest that a direct effect of ghrelin 
decreasing FAS expression and activity in the VMH may also contribute to this process 
(López et al. 2008a). Thus, it has been proposed that this effect prevents the decrease in 
hypothalamic malonyl-CoA in this nucleus (secondary to fasting-induced inactivation of 
ACC by AMPK) from reaching deleteriously low levels in the context of food 
deprivation. This action would increase the level of β-oxidation and in turn could 
compromise neuronal viability by thwarting lipid biosynthesis and by allowing 
potentially harmful neuronal fatty acid oxidation during fasting, a condition of low-
energy surplus. Supporting this concept, the reduction in FAS levels is not further 
decreased by prolonged fasting over a period of 48 h (López et al. 2006, 2008b). This 
suggests a tightly controlled FAS threshold in hypothalamic neurons, which is mediated 
by a mechanism involving the transcriptional regulation of SREBP-1 by AMPK (López 
et al. 2008a,b). In addition, the decrease in FAS after fasting or ghrelin administration is 
circumscribed to the VMH, where the GHS-R is highly expressed (Bennett et al. 1997, 
Guan et al. 1997, Tannenbaum et al. 1998, Willesen et al. 1999, Mitchell et al. 2001, 
Nogueiras et al. 2004, Smith 2005, Zigman et al. 2006, López et al. 2008a) is 
appealing. The VMH integrates peripheral signals alongside other hypothalamic nuclei 
and the brainstem, connected through specific neuronal projections (Tong et al. 2007). 
Thus, these data indicate that FAS in the VMH may play a role as a sensor of the 
nutritional state, besides its lipogenic effect (López et al. 2008a,b).  
 
Overall, these data show that hypothalamic fatty acid metabolism plays an 
integrative role in the short-term orexigenic response to ghrelin. However, the current 
data have challenged the long-term relevance of this mechanism, and thus its 
contribution to the increase in body mass and adiposity promoted by chronic central 
ghrelin administration (Tschop et al. 2000, Theander-Carrillo et al. 2006, Sangiao-
Alvarellos et al. 2009). The current data show that chronic central ghrelin 
administration does not elicit large changes in either AMPK or ACC activities in normal 
rats, but expressly inhibits FAS expression in the VMH and hypothalamic CPT1 activity 
(Sangiao-Alvarellos et al. 2010). Bearing in mind that chronic ghrelin treatment exerted 
a profound orexigenic action and parallel changes in AGRP and NPY expression in the 
ARC (Sangiao-Alvarellos et al. 2010), we are able to speculate that 1) in long-term 
altered nutritional conditions, AMPK-induced changes in hypothalamic fatty acid 
metabolism cannot play a key role in feeding control; in accordance with this hypothesis 
it has been suggested that hypothalamic fatty acid metabolism could be a regulatory 
mechanism engineered to maintain energy homeostasis in starvation (Andrews et al. 
2008, López et al. 2008a,b) and 2) contrary to short-term ghrelin action, chronic ghrelin 
inhibits hypothalamic CPT1 activity, which shows that in the long-term setting ghrelin 
could block hypothalamic β-oxidation, following the results obtained in the liver after 
long-term ghrelin treatment (Theander-Carrillo et al. 2006). The physiological 
significance of this action is uncertain, but it has been hypothesized that it could be a 
compensatory mechanism to the large orexigenic signal promoted by central 
hyperghrelinemia (Sangiao-Alvarellos et al. 2010). This concept originates from earlier 
data showing that pharmacological inhibition and/or genetic ablation of hypothalamic 
CPT1 (Obici et al. 2003, Pocai et al. 2006, Wolfgang et al. 2006, Wolfgang & Lane 
2008) or overexpression of MCD (He et al. 2006) induces the cytoplasmic accumulation 
of fatty acyl-CoA concentration and decreases food intake and body weight.  
GH-dependent effects of ghrelin on hypothalamic lipid metabolism 
In addition to its role in the modulation of energy homeostasis, ghrelin also controls 
the secretion of GH, by acting as a powerful GHS in rodents and humans (Kojima et al. 
1999, Masuda et al. 2000, Peino et al. 2000, Takaya et al. 2000). There are several 
studies highlighting the importance of GH signaling on the effect of ghrelin on 
metabolism. In spite of data demonstrating that GH-deficient rats show weight gain and 
adiposity induced by ghrelin (Tschop et al. 2000, Wren et al. 2000, Nakazato et al. 
2001, Wren et al. 2001b), i.c.v. ghrelin treatment did not increase food intake in GH 
receptor gene-deficient mice (Egecioglu et al. 2006) and ghrelin failed to increase the 
expression of GHS-R in the ARC of dwarf rats (Nogueiras et al. 2004). Examination of 
ghrelin's effect on the fatty acid metabolism pathway in the hypothalamus of GH-
deficient dwarf rats showed increased pAMPK levels after chronic ghrelin 
administration, without changes in CPT1 activity (which is decreased in dwarf rats) and 
no change in FAS mRNA and protein expression (Sangiao-Alvarellos et al. 2010). 
These data indicate that the actions of ghrelin on hypothalamic fatty acid metabolism 
are independent of GH and, in contrast to normal rats, chronic ghrelin-induced 
hyperphagia in dwarf rats could be mediated by specific modulation of the lipogenic 
pathway. It is possible that this effect is due to elevated hypothalamic GHS-R 
expression in GH deficiency (Nogueiras et al. 2004), but the molecular foundation of 
the effect is yet to be determined. In this context, it would be critical to assess whether 
that action is mediated by the canonical BSX–FOXO1–pCREP pathway. Equally 
intriguing are the results showing that ghrelin-mediated decrease in FAS expression is 
blunted in the VMH of dwarf rats. As stated earlier, to avert a harmful drop in the levels 
of malonyl-CoA in the hypothalamus, data have shown that a physiological adaptive 
mechanism causes ghrelin- and fasting-induced decreases in FAS levels in the VMH 
(Andrews et al. 2008, López et al. 2008a,b). Since this regulatory mechanism is lost in 
dwarf rats, it is possible that an accumulation of toxic lipid species and lipotoxicity-
associated phenomena, such as ER stress (Hosoi et al. 2008, Zhang et al. 2008, Ozcan 
et al. 2009, Won et al. 2009, Martínez de Morentin et al. 2010b), might be caused by 
altered fatty acid fluxes in the hypothalamic neurons, which may be induced from GH-
deficiency, thus hindering hypothalamic metabolism in these animals. Further work will 
be necessary to address these issues. As seen in this evidence, the hypothalamus of 
dwarf rats displayed decreases in both de novo lipogenesis and β-oxidation after chronic 
ghrelin treatment (Sangiao-Alvarellos et al. 2010). These results are quite opposite to 
the observed data in normal rats, where ghrelin decreases both de novo lipogenesis but 
stimulates β-oxidation in the hypothalamus (Andersson et al. 2004, Kola et al. 2005, 
2008, Andrews et al. 2008, López et al. 2008a, Sangiao-Alvarellos et al. 2010) and 
suggest that ghrelin actions on hypothalamic fatty acid metabolism are GH independent. 
Considering the essential role of GH on peripheral lipid metabolism (Maccario et al. 
2000, van der Lely et al. 2004, van der Lely 2009), to determine the physiological 
relevance of these data is difficult. Following this theme, current findings indicate that 
GH dependency is not shown in the central ghrelin effects on either adipose or hepatic 
liver metabolism (Sangiao-Alvarellos et al. 2009).  
Central ghrelin actions on hypothalamic CAMKK2 
The ghrelin receptor, a Gq-coupled receptor, increases intracellular Ca
2+
 via 
phospholipase C and protein kinase C induction (Garcia et al. 2001, van der Lely et al. 
2004). Since rises in intracellular Ca
2+
 lead to activation of CAMKK2, an upstream 
AMPK kinase (Hawley et al. 2005, Woods et al. 2005), which is abundantly expressed 
in the ARC (Anderson et al. 2008), it has recently been proposed that this interaction 
could be important for feeding control. Supporting this hypothesis, the CAMKK2 KO 
mice (CAMKK2 KO) showed reduced expression of AGRP and NPY in the ARC 
(Anderson et al. 2008). Consistent with this, hypothalamic AMPK activity is also 
decreased in the CAMKK2 KO mice, which also show resistance to the ghrelin 
orexigenic effect (Anderson et al. 2008). In keeping with these observations, STO-609, 
a selective CAMKK2 inhibitor, inhibited NPY expression and reduced food intake and 
body weight in wild-type animals. Moreover, the loss of CAMKK2 protects mice from 
high-fat diet (HFD)-induced obesity, insulin resistance, and glucose intolerance 
(Anderson et al. 2008).  
Central ghrelin actions on peripheral lipid metabolism 
In addition to its role as the main modulator of hypothalamic lipid metabolism, 
recent data have also highlighted the role of ghrelin as a main modulator of peripheral 
lipid metabolism (Nogueiras et al. 2010). Central administration of ghrelin directly 
elicits adiposity by the stimulation of the lipogenic program in the white adipose tissue 
(WAT) in a food intake-independent manner (Theander-Carrillo et al. 2006, Nogueiras 
et al. 2007, Sangiao-Alvarellos et al. 2009, Andrews et al. 2010). In particular, central 
ghrelin administration stimulates AGRP/NPY neurons, which promotes the blockade of 
the melanocortin receptors 3 and 4 (MC3R and MC4R) and regulation of peripheral 
lipid metabolism through the SNS (Theander-Carrillo et al. 2006, Nogueiras et al. 
2007). As a result of these events, mRNA expression of various fat storage-promoting 
enzymes such as lipoprotein lipase (LPL), ACCα, FAS, and stearoyl-CoA desaturase-1 
(SCD1) is induced in WAT; on the other hand, the rate-limiting step in fat oxidation, 
CPT1, was decreased (Fig. 4; Theander-Carrillo et al. 2006, Sangiao-Alvarellos et al. 
2009, Andrews et al. 2010). Opposite expression patterns seen throughout i.c.v. ghrelin 
treatment were discovered in ghrelin KO mice. This discovery is consistent with this 
pharmacological data, recognizing the fact that the endogenous ghrelin system is a 
major factor in the physiological regulation of WAT metabolism (Nogueiras et al. 
2010). Specifically, Lpl and Scd1 mRNA expression was decreased in ghrelin KO mice 
compared with wild-type controls (Theander-Carrillo et al. 2006). Taken as a whole, 
this evidence indicates that central ghrelin action is of physiological relevance in the 
control of adipocyte metabolism and indicated that ghrelin could elicit the processes in 
the central nervous system in readiness for the ingestion of food (Nogueiras et al. 2010). 
Interestingly, central ghrelin reduced UCP1 and UCP3 in BAT (Theander-Carrillo et al. 
2006), suggesting that, besides increased lipogenesis, decreased thermogenesis and 
energy expenditure might contribute to adiposity. In this sense, a recent and elegant 
report form Horvath et al. demonstrated that the feeding-independent lipogenic actions 
of ghrelin are enhanced in mice lacking UCP2 (UCP2 KO; Andrews et al. 2010). The 
molecular mechanisms under this effect are not fully understood, but UCP2 KO mice 
display high expression of lipogenic enzymes, such as FAS, SCD1, and LPL, and 
decreased expression of CPT1a in WAT (Andrews et al. 2010). These data correlate 
with the higher susceptibility to gain weight in an HFD observed in this model (Joseph 
et al. 2002), as well as with that well-established UCP2-mediated increase in fatty acid 
oxidation under fasting (Andrews et al. 2008, Pecqueur et al. 2008, Sheets et al. 2008). 
These data identify UCP2 as a common factor modulating energy homeostasis at 
hypothalamic (Andrews et al. 2008) and peripheral level (Andrews et al. 2010). 
Moreover, they suggest that ghrelin-induced UCP2 expression in WAT may be a 
protective mechanism to prevent excessive weight gain and obesity. Additional work 
will be required to address whether the AMPK–malonyl-CoA–CPT1–UCP2 axis is 
specific to the actions of ghrelin on feeding and peripheral lipogenesis or a common 
mechanism for hormonal signals modulating both processes, such as leptin (Pocai et al. 
2005b, Buettner et al. 2006, 2008), insulin (Obici et al. 2002a,b, Pocai et al. 2005a, 
Plum et al. 2006, Koch et al. 2008), melanocortins (Nogueiras et al. 2007), RSTN 
(Vázquez et al. 2008), and GLP-1 (Nogueiras et al. 2009).  
 
 
 
Figure 4. Central ghrelin actions on peripheral lipid metabolism. Ghrelin stimulates agouti-related 
peptide/neuropeptide Y (AGRP/NPY) neurons. This action leads to a blockade of the melanocortin receptor 3 
and 4 (MC3R and MC4R) by AGRP and subsequent modulation of peripheral lipid metabolism through the 
sympathetic nervous system (SNS). Blockade of MC3R and MC4R increases lipid storage and adiposity.  
 
  
GH-dependent effects of ghrelin on peripheral lipid metabolism 
Considering the role of ghrelin as a GHS (Kojima et al. 1999, Masuda et al. 2000, 
Peino et al. 2000, Takaya et al. 2000), as well as the important actions of GH on 
peripheral lipid metabolism (Maccario et al. 2000, van der Lely et al. 2004, van der 
Lely 2009), we have recently examined the effects of chronic central ghrelin 
administration on peripheral lipid metabolism in dwarf rats. Our results indicate that 
central chronic ghrelin administration regulates adipose lipid metabolism, mainly in a 
GH-independent manner, as a result of increased mRNA, protein expression, and 
activity levels of ACCα, FAS, and SCD1, which increased in dwarf rats when compared 
with normal wild-type rats (Sangiao-Alvarellos et al. 2009). Conversely, central ghrelin 
regulates hepatic de novo lipogenesis in a GH-independent manner but fatty acid 
oxidation in a GH-dependent manner, because CPT1 was inhibited only in normal rats 
(Sangiao-Alvarellos et al. 2009). Furthermore, and in contrast to the hypothalamus 
(Andrews et al. 2008, López et al. 2008a,b), we showed that in peripheral tissues the 
increased ghrelin levels during food deprivation do not mediate the effects of fasting. In 
these tissues, starvation downregulates the expression of lipogenic enzymes, and 
activates (in the liver) or downregulates (in WAT) CPT1, which are the opposite effects 
to those observed after the ghrelin treatment (Sangiao-Alvarellos et al. 2009).  
Concluding remarks 
The positives of ensuring accurate regulation of homeostatic systems are complexity 
and redundancy. Lipid metabolism is a central element, which modulates energy 
balance downstream the ghrelin signaling pathway. Not only do recent anatomical and 
pharmacological data demonstrate this, but it is also backed up by current genetic and 
physiological evidence as well. At the hypothalamic level, the short-term (but not the 
long-term) orexigenic effect of ghrelin is mediated by AMPK-driven changes in 
hypothalamic lipid metabolism (ACC, FAS, and CPT1) and UCP2 that subsequently 
influence neuropeptide gene expression through the transcription factors BSX, FOXO1, 
and pCREB (Andersson et al. 2004, Kola et al. 2005, 2008, Andrews et al. 2008, López 
et al. 2008a,b, Lage et al. 2010, Sangiao-Alvarellos et al. 2010). Similarly, central 
ghrelin also acts by modulating the adipose lipogenic pathway through the SNS in a 
GH-independent but UCP2-dependent manner (Theander-Carrillo et al. 2006, Sangiao-
Alvarellos et al. 2009, Andrews et al. 2010).  
 
On the basis of these data, it is tempting to speculate that ghrelin favors energy 
stores in order to minimize the negative effects on periods of food scarcity (Nogueiras et 
al. 2010). During fasting, increased ghrelin levels stimulate appetite and facilitates 
anabolic processes when food becomes available by triggering biological responses that 
modulate the efficiency of energy storage, i.e. increasing lipogenesis and inducing 
UCP2 in WAT, which shifts the organism from a negative energy balance state to a 
neutral energy balance state, avoiding overweight and obesity (Tsubone et al. 2005, 
Andrews et al. 2008, 2010, López et al. 2008a, Sangiao-Alvarellos et al. 2009, 
Nogueiras et al. 2010). However, this mechanism, which was primarily designed as a 
response to fasting, under conditions of HFD (Wortley et al. 2005, Zigman et al. 2005) 
or GH deficiency (Sangiao-Alvarellos et al. 2009), seems to increase excessively 
positive energy balance and fat mass, which ultimately may lead to harmful pro-
obesogenic and diabetic states.  
 
Alternatively, a new and crucial link between ghrelin and lipids has been recently 
revealed by studying ghrelin O-acyl transferase (GOAT), the enzyme responsible for 
ghrelin acylation (Gonzalez et al. 2008, Gutierrez et al. 2008, Yang et al. 2008). Tschop 
and colleagues have elegantly demonstrated that GOAT is regulated by nutrient 
availability and depends on specific dietary lipids, such as medium-chain fatty acids, 
which act as acylation substrates (Kirchner et al. 2009). This evidence links ingested 
lipids to ghrelin action and suggests that, to obtain optimal nutrient partitioning, the 
availability of high caloric food is signaled to the hypothalamus through readily 
absorbable medium-chain fatty acids, originating from the GOAT–ghrelin system 
working as a nutrient sensor.  
 
Altogether, these data identify the ghrelin–lipid metabolism interaction as a key 
homeostatic process modulating energy balance. Further work will be necessary to 
investigate the therapeutic implication of the ghrelin–lipid metabolism partnership for 
the treatment of obesity and metabolic syndrome.  
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